HLA-A24 binding peptides of enhancer of zeste homolog 2
US7160545B2 · kind B2 · utility
0Cited by
2References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 23, 2005 |
| Grant date | Jan 9, 2007 |
| Priority date | — |
| Expiry date | Aug 23, 2025 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A cancer antigen peptide comprising an amino acid sequence shown in SEQ ID NO: 1 or 2, or a derivative thereof having the functionally equivalent property is provided. The provided cancer antigen peptide is a partial peptide derived from enhancer of zeste homolog 2, which is capable of binding to HLA-A24 antigen and is recognized by cytotoxic T lymphocytes. The cancer antigen peptide of the invention is useful for treatment and prevention of prostate cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.